SPHRF
Price
$0.08
Change
+$0.01 (+14.29%)
Updated
Aug 13 closing price
Capitalization
36.99M
SPHRY
Price
$0.96
Change
+$0.21 (+28.00%)
Updated
Aug 13 closing price
Capitalization
36.99M
4 days until earnings call
Interact to see
Advertisement

SPHRF vs SPHRY

Header iconSPHRF vs SPHRY Comparison
Open Charts SPHRF vs SPHRYBanner chart's image
Starpharma Holdings
Price$0.08
Change+$0.01 (+14.29%)
Volume$2.6K
Capitalization36.99M
Starpharma Holdings
Price$0.96
Change+$0.21 (+28.00%)
Volume$2.9K
Capitalization36.99M
SPHRF vs SPHRY Comparison Chart in %
Loading...
SPHRF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SPHRY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
SPHRF vs. SPHRY commentary
Aug 16, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is SPHRF is a Buy and SPHRY is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 16, 2025
Stock price -- (SPHRF: $0.08 vs. SPHRY: $0.88)
Brand notoriety: SPHRF and SPHRY are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: SPHRF: 10% vs. SPHRY: 66%
Market capitalization -- SPHRF: $36.99M vs. SPHRY: $36.99M
SPHRF [@Biotechnology] is valued at $36.99M. SPHRY’s [@Biotechnology] market capitalization is $36.99M. The market cap for tickers in the [@Biotechnology] industry ranges from $100.71B to $0. The average market capitalization across the [@Biotechnology] industry is $1.88B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

SPHRF’s FA Score shows that 1 FA rating(s) are green whileSPHRY’s FA Score has 1 green FA rating(s).

  • SPHRF’s FA Score: 1 green, 4 red.
  • SPHRY’s FA Score: 1 green, 4 red.
According to our system of comparison, both SPHRF and SPHRY are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

SPHRF’s TA Score shows that 5 TA indicator(s) are bullish while SPHRY’s TA Score has 4 bullish TA indicator(s).

  • SPHRF’s TA Score: 5 bullish, 2 bearish.
  • SPHRY’s TA Score: 4 bullish, 2 bearish.
According to our system of comparison, SPHRY is a better buy in the short-term than SPHRF.

Price Growth

SPHRF (@Biotechnology) experienced а +39.67% price change this week, while SPHRY (@Biotechnology) price change was +34.77% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +9.90%. For the same industry, the average monthly price growth was +26.70%, and the average quarterly price growth was +20.91%.

Reported Earning Dates

SPHRY is expected to report earnings on Aug 20, 2025.

Industries' Descriptions

@Biotechnology (+9.90% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SPHRF($37M) and SPHRY($37M) have the same market capitalization . SPHRY YTD gains are higher at: 36.989 vs. SPHRF (14.325). SPHRF (-13.7M) and SPHRY (-13.7M) have comparable annual earnings (EBITDA) . SPHRF (2.98M) and SPHRY (2.98M) have equivalent revenues.
SPHRFSPHRYSPHRF / SPHRY
Capitalization37M37M100%
EBITDA-13.7M-13.7M100%
Gain YTD14.32536.98939%
P/E RatioN/AN/A-
Revenue2.98M2.98M100%
Total CashN/AN/A-
Total DebtN/AN/A-
FUNDAMENTALS RATINGS
SPHRF vs SPHRY: Fundamental Ratings
SPHRF
SPHRY
OUTLOOK RATING
1..100
3234
VALUATION
overvalued / fair valued / undervalued
1..100
32
Undervalued
35
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9797
PRICE GROWTH RATING
1..100
4036
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/a75

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

SPHRF's Valuation (32) in the null industry is in the same range as SPHRY (35). This means that SPHRF’s stock grew similarly to SPHRY’s over the last 12 months.

SPHRF's Profit vs Risk Rating (100) in the null industry is in the same range as SPHRY (100). This means that SPHRF’s stock grew similarly to SPHRY’s over the last 12 months.

SPHRF's SMR Rating (97) in the null industry is in the same range as SPHRY (97). This means that SPHRF’s stock grew similarly to SPHRY’s over the last 12 months.

SPHRY's Price Growth Rating (36) in the null industry is in the same range as SPHRF (40). This means that SPHRY’s stock grew similarly to SPHRF’s over the last 12 months.

SPHRY's P/E Growth Rating (100) in the null industry is in the same range as SPHRF (100). This means that SPHRY’s stock grew similarly to SPHRF’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
SPHRFSPHRY
RSI
ODDS (%)
Bearish Trend 2 days ago
82%
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
69%
Bearish Trend 2 days ago
84%
Momentum
ODDS (%)
Bullish Trend 2 days ago
46%
Bullish Trend 2 days ago
74%
MACD
ODDS (%)
Bullish Trend 2 days ago
48%
Bullish Trend 2 days ago
62%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
39%
Bullish Trend 2 days ago
60%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
34%
Bullish Trend 2 days ago
52%
Advances
ODDS (%)
Bullish Trend 3 days ago
43%
Bullish Trend 3 days ago
63%
Declines
ODDS (%)
N/A
N/A
BollingerBands
ODDS (%)
N/A
N/A
Aroon
ODDS (%)
N/A
Bullish Trend 2 days ago
62%
View a ticker or compare two or three
Interact to see
Advertisement
SPHRF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SPHRY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
BONL0.75N/A
N/A
Bonal International, Inc.
VODAF5.75N/A
N/A
Vodacom Group Ltd.
OCGPF2.65N/A
N/A
Oceana Group Ltd.
GGAAF5.38N/A
N/A
Genesis Growth Tech Acquisition Corp.
STLJF55.98-0.17
-0.31%
Stella Jones Inc.

SPHRF and

Correlation & Price change

A.I.dvisor tells us that SPHRF and CGEN have been poorly correlated (+26% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that SPHRF and CGEN's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SPHRF
1D Price
Change %
SPHRF100%
N/A
CGEN - SPHRF
26%
Poorly correlated
-1.38%
SPHRY - SPHRF
25%
Poorly correlated
-7.84%
NURPF - SPHRF
23%
Poorly correlated
N/A
SOLTF - SPHRF
23%
Poorly correlated
N/A
ASPHF - SPHRF
22%
Poorly correlated
N/A
More

SPHRY and

Correlation & Price change

A.I.dvisor tells us that SPHRY and VACBF have been poorly correlated (+29% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that SPHRY and VACBF's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SPHRY
1D Price
Change %
SPHRY100%
-7.84%
VACBF - SPHRY
29%
Poorly correlated
+26.59%
TTNP - SPHRY
27%
Poorly correlated
+1.65%
SPHRF - SPHRY
25%
Poorly correlated
N/A
ASPHF - SPHRY
22%
Poorly correlated
N/A
INM - SPHRY
21%
Poorly correlated
-0.85%
More